Quantcast
Channel: WN.com - Articles related to Actelion to enter Phase II clinical development with new dual orexin receptor antagonist in patients with insomnia (Actelion Ltd)
Browsing all 480 articles
Browse latest View live

Desperately Seeking Shut-Eye

In the early 1970s, a colleague of Stanford University’s William Dement remarked on the resemblance of a narcolepsy patient’s symptoms to those of a recent canine patient he had read about. The...

View Article


Actelion receives marketing approval for Opsumit (macitentan) in pulmonary...

(Source: Actelion Ltd) ALLSCHWIL, SWITZERLAND - 26 March 2015 - Actelion (SIX: ATLN) announced today that Japan's Ministry of Health, Labor and Welfare granted marketing approval for Opsumit®...

View Article


Further data on selexipag (Uptravi) to be presented at CHEST 2015 Congress...

(Source: Actelion Ltd) ALLSCHWIL, SWITZERLAND - 22 October 2015 - Actelion Ltd (SIX: ATLN) today announced that further key data from the pivotal Phase III GRIPHON study with the investigational drug...

View Article

Actelion issues invitation to 2016 Annual General Meeting of Shareholders...

(Source: Actelion Ltd) ALLSCHWIL/BASEL, SWITZERLAND - 6 April 2016- Actelion Ltd (SIX: ATLN) today issued the formal invitation to the upcoming Annual General Meeting (AGM) of Shareholders on behalf of...

View Article

Further data on selexipag (Uptravi) and macitentan (Opsumit) to be presented...

(Source: Actelion Ltd) ALLSCHWIL, SWITZERLAND - 23 September 2015 - Actelion Ltd (SIX: ATLN) today announced that key data from the pivotal Phase III GRIPHON study with the investigational drug...

View Article


Actelion receives positive CHMP opinion for chlormethine gel (Ledaga) for the...

ALLSCHWIL/BASEL, SWITZERLAND - 16 December 2016 - Actelion Ltd (SIX: ATLN) announced today that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European...

View Article

Actelion receives positive CHMP opinion for chlormethine gel (Ledaga) for the...

(Source: Actelion Ltd) ALLSCHWIL/BASEL, SWITZERLAND - 16 December 2016- Actelion Ltd (SIX: ATLN) announced today that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee...

View Article

Actelion's Annual General Meeting of Shareholders held in Basel, Switzerland...

(Source: Actelion Ltd) ALLSCHWIL/BASEL, SWITZERLAND - 08 May 2015 - At today's Annual General Meeting (AGM) of Actelion Ltd (SIX: ATLN), held in Basel, Switzerland, shareholders voted in favor of all...

View Article


Actelion announces commencement of share repurchase program (Actelion Ltd)

(Source: Actelion Ltd) ALLSCHWIL, SWITZERLAND - 23 March 2015 - Actelion (SIX: ATLN) announced today that it has received approval from the relevant authorities to launch the repurchase of up to 10...

View Article


Actelion creates Vaxxilon together with the Max Planck Society (Actelion Ltd)

(Source: Actelion Ltd) ALLSCHWIL, SWITZERLAND - 26 June 2015 - Actelion Ltd (SIX: ATLN) today announced the creation of a start-up, together with the Max Planck Society, in the field of synthetic...

View Article

Actelion to present at the 33rd J.P. Morgan Healthcare Conference -...

(Source: Actelion Ltd) ALLSCHWIL/BASEL, SWITZERLAND - 12 January 2015- Actelion Ltd (SIX: ATLN) announced today that Jean-Paul Clozel, Chief Executive Officer of Actelion, will present at the J. P....

View Article

Actelion receives marketing approval for Opsumit (macitentan) in pulmonary...

(Source: Actelion Ltd) ALLSCHWIL, SWITZERLAND - 26 March 2015 - Actelion (SIX: ATLN) announced today that Japan's Ministry of Health, Labor and Welfare granted marketing approval for Opsumit®...

View Article

CORRECTION: JOHNSON & JOHNSON TO ACQUIRE ACTELION FOR $30 BILLION WITH...

In the previous press release the companies omitted the cash amount with which R&D NewCo will launch. This has now been rectified and noted as CHF 1 billion. Actelion Shareholders to Receive $280...

View Article


JOHNSON & JOHNSON TO ACQUIRE ACTELION FOR $30 BILLION WITH SPIN-OUT OF NEW...

For Immediate Release� Actelion Shareholders to Receive $280 Per Actelion Share in All-Cash Tender Offer to be Launched by Johnson & Johnson and One Share of New R&D Company for Each Actelion...

View Article

CORRECTION: JOHNSON & JOHNSON TO ACQUIRE ACTELION FOR $30 BILLION WITH...

(Source: Actelion Ltd) In the previous press release the companies omitted the cash amount with which R&D NewCo will launch. This has now been rectified and noted as CHF 1 billion. Actelion...

View Article


JOHNSON & JOHNSON TO ACQUIRE ACTELION FOR $30 BILLION WITH SPIN-OUT OF NEW...

(Source: Actelion Ltd) For Immediate Release Actelion Shareholders to Receive $280 Per Actelion Share in All-Cash Tender Offer to be Launched by Johnson & Johnson and One Share of New R&D...

View Article

Actelion announces results of the MAESTRO study with macitentan in patients...

ALLSCHWIL/BASEL, SWITZERLAND - 23 January 2017 - Actelion Ltd (SIX: ATLN) today announced that the MAESTRO study to assess the efficacy, safety and tolerability of macitentan in patients with pulmonary...

View Article


Actelion announces results of the MAESTRO study with macitentan in patients...

(Source: Actelion Ltd) ALLSCHWIL/BASEL, SWITZERLAND - 23 January 2017 - Actelion Ltd (SIX: ATLN) today announced that the MAESTRO study to assess the efficacy, safety and tolerability of macitentan in...

View Article

Johnson & Johnson to Acquire Actelion for $30 Billion With Spin-Out of New...

(Source: Janssen Pharmaceuticals Inc) Actelion Shareholders to Receive $280 Per Actelion Share in All-Cash Tender Offer to be Launched by Johnson & Johnson and One Share of New R&D Company for...

View Article

Actelion Using Combination Strategy to Attack Multiple Sclerosis

Actelion Ltd. is seeking more effective treatments for people suffering from multiple sclerosis by following a strategy that’s worked in treating HIV, cancer and heart failure -- combining medicines to...

View Article
Browsing all 480 articles
Browse latest View live


<script src="https://jsc.adskeeper.com/r/s/rssing.com.1596347.js" async> </script>